Novo Nordisk Pharma Applies For Approval For Diabetes Drug Liraglutide
This article was originally published in PharmAsia News
Executive SummaryTokyo based Novo Nordisk Pharma applied for approval for liraglutide, a once-daily human GLP-1 analog for the treatment of type 2 diabetes. In Phase 3 domestic clinical trials in Japan, liraglutide was shown to significantly reduce HbA1c level after 24 weeks of administrating of either the drug alone or combined with sulfonylureas. When combined with sulfonylureas, about half of the patients had their HbA1c level reduced below 6.5 percent. The treatment did not run a risk of inducing hypoglycaemia. Novo Nordisk applied for approval for liraglutide with U.S. FDA and EMEA on May 23. (Click here for more - Japanese language
You may also be interested in...
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.